Chemotherapy advances in small-cell lung cancer

Chan, Bryan A. and Coward, Jermaine I. G. (2013) Chemotherapy advances in small-cell lung cancer. Journal of Thoracic Disease, 5 SUPPL.5: S565-S578. doi:10.3978/j.issn.2072-1439.2013.07.43

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Chan, Bryan A.
Coward, Jermaine I. G.
Title Chemotherapy advances in small-cell lung cancer
Journal name Journal of Thoracic Disease   Check publisher's open access policy
ISSN 2072-1439
2077-6624
Publication date 2013-10-01
Year available 2011
Sub-type Critical review of research, literature review, critical commentary
DOI 10.3978/j.issn.2072-1439.2013.07.43
Open Access Status PMC
Volume 5
Issue SUPPL.5
Start page S565
End page S578
Total pages 14
Place of publication Hong Kong, Hong Kong
Publisher Pioneer Bioscience Publishing Company
Language eng
Subject 2740 Pulmonary and Respiratory Medicine
Abstract Although chemotherapeutic advances have recently been heralded in lung adenocarcinomas, such success with small-cell lung cancer (SCLC) has been ominously absent. Indeed, the dismal outlook of this disease is exemplified by the failure of any significant advances in first line therapy since the introduction of the current standard platinum-etoposide doublet over 30 years ago. Moreover, such sluggish progress is compounded by the dearth of FDA-approved agents for patients with relapsed disease. However, over the past decade, novel formulations of drug classes commonly used in SCLC (e.g. topoisomerase inhibitors, anthracyclines, alkylating and platinum agents) are emerging as potential alternatives that could effectively add to the armamentarium of agents currently at our disposal. This review is introduced with an overview on the historical development of chemotherapeutic regimens used in this disease and followed by the recent encouraging advances witnessed in clinical trials with drugs such as amrubicin and belotecan which are forging new horizons for future treatment algorithms.
Keyword Small cell lung cancer (SCLC)
amrubicin
belotecan
picoplatin
relapsed SCLC
Phase-Ii Trial
Cooperative-Oncology-Group
Thymidylate Synthase Expression
Previously Untreated Patients
Council Comparative Trial
Cisplatin Plus Etoposide
Bronchogenic-Carcinoma
2Nd-Line Therapy
Randomized-Trial
Single-Agent
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2014 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 43 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 50 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 15 Dec 2013, 10:10:53 EST by System User on behalf of School of Medicine